| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.646 | 0.013 | 0.646 | Aldehyde oxidase inhibitor | 0.482 0.035 DBMET00322 | ||
| 0.596 | 0.004 | 0.596 | Sigma receptor agonist | 0.312 0.037 DBMET00322 | ||
| 0.572 | 0.011 | 0.572 | GABA C receptor rho-3 antagonist | |||
| 0.55 | 0.009 | 0.55 | Superoxide dismutase inhibitor | 0.339 0.039 DBMET00322 | ||
| 0.54 | 0.022 | 0.54 | 5 Hydroxytryptamine release inhibitor | 0.325 0.138 DBMET00322 | ||
| 0.513 | 0.004 | 0.513 | Tyrosine 3 hydroxylase inhibitor | 0.326 0.023 DBMET00322 | ||
| 0.494 | 0.016 | 0.494 | Cardiotonic | 0.256 0.078 DBMET00322 | ||
| 0.46 | 0.005 | 0.46 | Anesthetic local | 0.096 0.087 DBMET00322 | ||
| 0.457 | 0.006 | 0.457 | MAP kinase kinase 2 inhibitor | |||
| 0.447 | 0.015 | 0.447 | Peroxidase inhibitor | 0.427 0.017 DBMET00322 | ||
| 0.434 | 0.073 | 0.434 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | |||
| 0.379 | 0.026 | 0.379 | Psychostimulant | |||
| 0.356 | 0.013 | 0.356 | Lipocortins synthesis antagonist | 0.19 0.063 DBMET00322 | ||
| 0.35 | 0.01 | 0.35 | Nav1.2 sodium channel blocker | |||
| 0.336 | 0.012 | 0.336 | Ca2+/calmodulin-dependent kinase II delta inhibitor | |||
| 0.318 | 0.009 | 0.318 | Chelator | 0.263 0.015 DBMET00322 | ||
| 0.358 | 0.05 | 0.358 | Spasmolytic | |||
| 0.314 | 0.011 | 0.314 | DNA intercalator | 0.159 0.039 DBMET00322 | ||
| 0.335 | 0.034 | 0.335 | Interleukin agonist | |||
| 0.332 | 0.034 | 0.332 | Ca2+/calmodulin-dependent protein kinase inhibitor | |||
| 0.305 | 0.017 | 0.305 | Neuropeptide Y2 antagonist | 0.204 0.112 DBMET00322 | ||
| 0.32 | 0.033 | 0.32 | Ca2+/calmodulin-dependent kinase I alpha inhibitor | |||
| 0.33 | 0.045 | 0.33 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | |||
| 0.295 | 0.013 | 0.295 | Nitric-oxide synthase stimulant | |||
| 0.296 | 0.026 | 0.296 | Peptidyltransferase inhibitor | 0.288 0.029 DBMET00322 | ||
| 0.318 | 0.048 | 0.318 | Insulysin inhibitor | |||
| 0.282 | 0.012 | 0.282 | MAP kinase kinase 3 inhibitor | |||
| 0.28 | 0.023 | 0.28 | I kappa B kinase epsilon inhibitor | |||
| 0.309 | 0.054 | 0.309 | DNA damaging | |||
| 0.289 | 0.036 | 0.289 | Anesthetic general | 0.187 0.082 DBMET00322 | ||
| 0.35 | 0.1 | 0.35 | Histamine release inhibitor | 0.224 0.177 DBMET00322 | ||
| 0.288 | 0.038 | 0.288 | 5 Hydroxytryptamine 1E antagonist | |||
| 0.269 | 0.028 | 0.269 | Focal adhesion kinase 2 inhibitor | |||
| 0.248 | 0.012 | 0.248 | GABA C receptor rho-2 antagonist | |||
| 0.247 | 0.014 | 0.247 | Nav1.3 sodium channel blocker | |||
| 0.235 | 0.003 | 0.235 | Topoisomerase II beta inhibitor | 0.062 0.021 DBMET00322 | ||
| 0.265 | 0.036 | 0.265 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.166 0.115 DBMET00322 | ||
| 0.272 | 0.056 | 0.272 | Gastrin inhibitor | |||
| 0.233 | 0.021 | 0.233 | Adenylate cyclase inhibitor | |||
| 0.297 | 0.09 | 0.297 | Vasodilator, coronary | |||
| 0.225 | 0.02 | 0.225 | Death-associated protein kinase 2 inhibitor | 0.164 0.077 DBMET00322 | ||
| 0.285 | 0.085 | 0.285 | Interleukin 2 agonist | |||
| 0.25 | 0.052 | 0.25 | ErbB-1 antagonist | |||
| 0.265 | 0.067 | 0.265 | 5 Hydroxytryptamine uptake stimulant | 0.206 0.14 DBMET00322 | ||
| 0.227 | 0.031 | 0.227 | Phospholipase C inhibitor | 0.151 0.105 DBMET00322 | ||
| 0.238 | 0.044 | 0.238 | LIM domain kinase 1 inhibitor | |||
| 0.251 | 0.059 | 0.251 | MAP-kinase-activated kinase 5 inhibitor | |||
| 0.205 | 0.013 | 0.205 | Telomerase inhibitor | 0.104 0.032 DBMET00322 | ||
| 0.271 | 0.088 | 0.271 | Immunostimulant | |||
| 0.193 | 0.009 | 0.193 | GABA C receptor rho-1 antagonist | |||
| 0.207 | 0.024 | 0.207 | Alkylator | |||
| 0.225 | 0.053 | 0.225 | Ca2+/calmodulin-dependent kinase II gamma inhibitor | |||
| 0.226 | 0.057 | 0.226 | DNA methyltransferase I inhibitor | |||
| 0.229 | 0.061 | 0.229 | DNA methylase inhibitor | |||
| 0.199 | 0.033 | 0.199 | Catenin beta inhibitor | |||
| 0.182 | 0.017 | 0.182 | GABA C receptor antagonist | |||
| 0.179 | 0.015 | 0.222 | Porphobilinogen synthase inhibitor | 0.222 0.01 DBMET00322 | DBMET00322 | |
| 0.195 | 0.035 | 0.195 | Acetylcholinesterase inhibitor | |||
| 0.174 | 0.016 | 0.174 | Sphingomyelinase inhibitor | 0.094 0.067 DBMET00322 | ||
| 0.172 | 0.014 | 0.172 | NADH dehydrogenase inhibitor | 0.144 0.019 DBMET00322 | ||
| 0.167 | 0.009 | 0.167 | Acetylcholine release stimulant | |||
| 0.157 | 0.003 | 0.157 | Epithelial sodium channel blocker | |||
| 0.17 | 0.016 | 0.17 | Folate antagonist | |||
| 0.193 | 0.041 | 0.193 | Heat shock protein 90 antagonist | |||
| 0.164 | 0.015 | 0.164 | Electrolyte absorption antagonist | |||
| 0.265 | 0.117 | 0.265 | Transcription factor NF kappa B inhibitor | |||
| 0.151 | 0.005 | 0.151 | Heat shock protein 90 beta antagonist | |||
| 0.194 | 0.049 | 0.194 | Cholinergic | |||
| 0.174 | 0.031 | 0.174 | Cyclooxygenase 3 inhibitor | |||
| 0.177 | 0.035 | 0.177 | Aldehyde dehydrogenase inhibitor | 0.13 0.061 DBMET00322 | ||
| 0.227 | 0.088 | 0.227 | Calpain inhibitor | |||
| 0.172 | 0.033 | 0.172 | Adenylate cyclase stimulant | 0.129 0.104 DBMET00322 | ||
| 0.211 | 0.072 | 0.211 | Amyloid beta aggregation inhibitor | 0.205 0.075 DBMET00322 | ||
| 0.142 | 0.004 | 0.142 | Phospholipase D inhibitor | |||
| 0.169 | 0.032 | 0.169 | Alpha 2b adrenoreceptor antagonist | |||
| 0.163 | 0.026 | 0.163 | Carbonic anhydrase XV inhibitor | |||
| 0.297 | 0.16 | 0.297 | Calcium channel L-type activator | |||
| 0.181 | 0.045 | 0.181 | Toll-Like receptor 9 antagonist | |||
| 0.225 | 0.088 | 0.225 | DNA synthesis inhibitor | |||
| 0.16 | 0.025 | 0.16 | Potassium channel (Ca-activated) activator | |||
| 0.144 | 0.011 | 0.144 | Histamine H2 receptor antagonist | |||
| 0.264 | 0.131 | 0.264 | Calcium channel activator | |||
| 0.159 | 0.027 | 0.159 | Papain-like protease (SARS coronavirus) inhibitor | |||
| 0.268 | 0.137 | 0.268 | Calpain 2 inhibitor | |||
| 0.204 | 0.074 | 0.204 | Ca2+/calmodulin-dependent kinase II beta inhibitor | |||
| 0.138 | 0.009 | 0.138 | Histone deacetylase inhibitor | |||
| 0.171 | 0.042 | 0.171 | Toll-Like receptor antagonist | |||
| 0.132 | 0.006 | 0.132 | Estrogen-related receptor beta agonist | 0.093 0.035 DBMET00322 | ||
| 0.156 | 0.032 | 0.156 | Butyrylcholinesterase inhibitor | |||
| 0.175 | 0.055 | 0.175 | Acetylcholine M1 receptor antagonist | |||
| 0.138 | 0.019 | 0.138 | Toll-Like receptor 3 antagonist | |||
| 0.175 | 0.057 | 0.175 | Diuretic | |||
| 0.141 | 0.03 | 0.141 | Adenylate kinase inhibitor | 0.1 0.068 DBMET00322 | ||
| 0.157 | 0.046 | 0.157 | Nav1.6 sodium channel blocker | |||
| 0.153 | 0.044 | 0.153 | Cathepsin H inhibitor | |||
| 0.3 | 0.194 | 0.3 | Caspase 9 stimulant | 0.262 0.239 DBMET00322 | ||
| 0.161 | 0.056 | 0.161 | Hemostatic | |||
| 0.16 | 0.055 | 0.16 | Ca2+/calmodulin-dependent protein kinase kinase B inhibitor | |||
| 0.123 | 0.019 | 0.123 | Myeloperoxidase inhibitor | |||
| 0.108 | 0.004 | 0.108 | Dihydropteroate synthase inhibitor | |||
| 0.184 | 0.081 | 0.184 | Growth factor agonist | |||
| 0.137 | 0.035 | 0.137 | Platelet activating factor alpha antagonist | |||
| 0.129 | 0.027 | 0.129 | MAP kinase kinase 1 inhibitor | |||
| 0.105 | 0.004 | 0.105 | Ryanodine receptor antagonist | |||
| 0.16 | 0.06 | 0.16 | CF transmembrane conductance regulator agonist | |||
| 0.149 | 0.05 | 0.149 | Topoisomerase II inhibitor | |||
| 0.152 | 0.054 | 0.152 | Alpha-N-acetylglucosaminidase inhibitor | 0.13 0.069 DBMET00322 | ||
| 0.166 | 0.069 | 0.166 | Interleukin 6 antagonist | |||
| 0.139 | 0.042 | 0.139 | Falcipain 3 inhibitor | |||
| 0.163 | 0.067 | 0.163 | Cyclin-dependent kinase 8 inhibitor | |||
| 0.115 | 0.02 | 0.165 | Phenylalanine 4-hydroxylase inhibitor | 0.165 0.01 DBMET00322 | DBMET00322 | |
| 0.123 | 0.028 | 0.123 | Polo-like kinase-1 inhibitor | |||
| 0.17 | 0.077 | 0.17 | Tumour necrosis factor antagonist | |||
| 0.172 | 0.08 | 0.172 | MAP kinase kinase 5 inhibitor | |||
| 0.265 | 0.172 | 0.265 | MAP kinase kinase 6 inhibitor | |||
| 0.127 | 0.036 | 0.127 | Interleukin 2 antagonist | |||
| 0.185 | 0.093 | 0.185 | 5 Hydroxytryptamine 3E antagonist | |||
| 0.125 | 0.035 | 0.125 | Nitric-oxide synthase inhibitor | |||
| 0.094 | 0.006 | 0.094 | Sodium/calcium exchanger inhibitor | |||
| 0.151 | 0.064 | 0.151 | Ribosomal protein S6 kinase inhibitor | |||
| 0.118 | 0.031 | 0.118 | Histamine N-methyltransferase inhibitor | |||
| 0.161 | 0.076 | 0.161 | Heat shock protein 90 alpha antagonist | |||
| 0.137 | 0.053 | 0.137 | Acetylcholine muscarinic antagonist | |||
| 0.088 | 0.004 | 0.088 | Delayed rectifier potassium channel blocker | |||
| 0.19 | 0.106 | 0.19 | Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase inhibitor | |||
| 0.091 | 0.009 | 0.091 | Histone deacetylase class I inhibitor | |||
| 0.189 | 0.107 | 0.189 | Antiamyloidogenic | |||
| 0.111 | 0.031 | 0.111 | I kappa B kinase inhibitor | |||
| 0.087 | 0.009 | 0.087 | Carbonic anhydrase IV inhibitor | |||
| 0.092 | 0.015 | 0.092 | CC chemokine 2 receptor antagonist | |||
| 0.082 | 0.007 | 0.082 | Adenylate cyclase 1 inhibitor | |||
| 0.123 | 0.048 | 0.123 | GABA C receptor agonist | |||
| 0.093 | 0.019 | 0.093 | S-adenosyl-L-methionine decarboxylase inhibitor | |||
| 0.08 | 0.008 | 0.08 | Thymidylate synthase inhibitor | |||
| 0.163 | 0.091 | 0.163 | TRKC antagonist | |||
| 0.145 | 0.073 | 0.145 | Neuropeptide Y1 antagonist | |||
| 0.099 | 0.03 | 0.099 | Interferon agonist | |||
| 0.098 | 0.029 | 0.098 | Aminopeptidase I inhibitor | |||
| 0.128 | 0.059 | 0.128 | Proteasome inhibitor | |||
| 0.081 | 0.013 | 0.081 | 5 Hydroxytryptamine 4 antagonist | |||
| 0.121 | 0.053 | 0.121 | Ferrochelatase inhibitor | |||
| 0.083 | 0.02 | 0.083 | I kappa B kinase 2 inhibitor | |||
| 0.08 | 0.018 | 0.08 | Gonadotropin-releasing hormone receptor agonist | |||
| 0.107 | 0.045 | 0.107 | Lanosterol 14 alpha demethylase inhibitor | |||
| 0.08 | 0.018 | 0.08 | Histone deacetylase SIRT3 inhibitor | |||
| 0.066 | 0.005 | 0.066 | Dopamine autoreceptor agonist | |||
| 0.117 | 0.057 | 0.117 | Mucolytic | |||
| 0.069 | 0.008 | 0.069 | Plasmepsin II inhibitor | |||
| 0.19 | 0.13 | 0.19 | 5 Hydroxytryptamine release stimulant | |||
| 0.115 | 0.055 | 0.115 | Aminopeptidase B inhibitor | |||
| 0.1 | 0.041 | 0.1 | Bcr-Abl kinase inhibitor | |||
| 0.097 | 0.039 | 0.097 | Granulocyte macrophage colony stimulating factor agonist | |||
| 0.083 | 0.027 | 0.083 | Potassium channel (Tandem pore domain) blocker | |||
| 0.104 | 0.048 | 0.104 | Potassium channel (Voltage-sensitive) activator | |||
| 0.093 | 0.038 | 0.093 | D-Ala-D-Ala ligase inhibitor | |||
| 0.074 | 0.019 | 0.074 | Glycine transporter 2 inhibitor | |||
| 0.126 | 0.071 | 0.126 | Toll-Like receptor 2 antagonist | |||
| 0.086 | 0.032 | 0.086 | MAP kinase kinase 7 inhibitor | |||
| 0.132 | 0.078 | 0.132 | Histone deacetylase SIRT1 inhibitor | |||
| 0.081 | 0.028 | 0.081 | Adenosine A1 receptor antagonist | |||
| 0.071 | 0.018 | 0.071 | Beta 2 adrenoreceptor agonist | |||
| 0.089 | 0.037 | 0.089 | Glutamate dehydrogenase inhibitor | 0.069 0.058 DBMET00322 | ||
| 0.104 | 0.053 | 0.104 | Glutamate (mGluR7) agonist | |||
| 0.053 | 0.002 | 0.053 | Estrogen-related receptor gamma agonist | 0.021 0.01 DBMET00322 | ||
| 0.108 | 0.058 | 0.108 | Urease inhibitor | |||
| 0.076 | 0.027 | 0.076 | Carbonic anhydrase I inhibitor | |||
| 0.108 | 0.059 | 0.108 | Alpha 2c adrenoreceptor antagonist | |||
| 0.135 | 0.087 | 0.135 | Cytidine deaminase inhibitor | |||
| 0.158 | 0.11 | 0.158 | Death-associated protein kinase 3 inhibitor | |||
| 0.073 | 0.025 | 0.073 | Acyl-CoA dehydrogenase inhibitor | |||
| 0.068 | 0.021 | 0.068 | Phosphorylase inhibitor | |||
| 0.165 | 0.119 | 0.165 | Histone acetyltransferase inhibitor | |||
| 0.06 | 0.014 | 0.06 | Growth hormone secretagogue receptor antagonist | |||
| 0.06 | 0.014 | 0.06 | AICAR transformylase inhibitor | |||
| 0.095 | 0.05 | 0.095 | Glutamate release inhibitor | |||
| 0.079 | 0.036 | 0.079 | Carbonic anhydrase inhibitor | |||
| 0.118 | 0.075 | 0.118 | Cholinergic antagonist | |||
| 0.089 | 0.047 | 0.089 | Topoisomerase II alpha inhibitor | |||
| 0.049 | 0.008 | 0.049 | Lysine carboxypeptidase inhibitor | |||
| 0.048 | 0.007 | 0.048 | Methionyl aminopeptidase 2 inhibitor | |||
| 0.075 | 0.034 | 0.075 | Potassium channel (ATP-sensitive) blocker | |||
| 0.059 | 0.019 | 0.059 | Factor III inhibitor | |||
| 0.053 | 0.014 | 0.053 | Histone deacetylase 9 inhibitor | |||
| 0.096 | 0.057 | 0.096 | Alcohol dehydrogenase inhibitor | 0.095 0.058 DBMET00322 | ||
| 0.114 | 0.076 | 0.114 | Acetylcholine antagonist | |||
| 0.082 | 0.044 | 0.082 | GABA aminotransferase inhibitor | |||
| 0.067 | 0.029 | 0.067 | Acetylcholine muscarinic agonist | |||
| 0.07 | 0.031 | 0.07 | 5 Hydroxytryptamine 5A antagonist | |||
| 0.062 | 0.024 | 0.062 | Alpha-mannosidase inhibitor | |||
| 0.092 | 0.055 | 0.092 | Pim-3 kinase inhibitor | |||
| 0.067 | 0.031 | 0.067 | Carbonic anhydrase II inhibitor | |||
| 0.103 | 0.067 | 0.103 | Topoisomerase I inhibitor | |||
| 0.13 | 0.095 | 0.13 | Thiol protease inhibitor | |||
| 0.082 | 0.048 | 0.082 | Fibroblast growth factor 3 antagonist | |||
| 0.085 | 0.05 | 0.085 | CC chemokine 5 receptor agonist | |||
| 0.066 | 0.031 | 0.066 | Prolactin release inhibitor | |||
| 0.054 | 0.019 | 0.054 | Geranyltranstransferase inhibitor | |||
| 0.07 | 0.035 | 0.07 | Interferon inducer | |||
| 0.126 | 0.092 | 0.126 | Aurora-C kinase inhibitor | |||
| 0.085 | 0.052 | 0.085 | Platelet growth factor antagonist | |||
| 0.084 | 0.052 | 0.084 | Adrenaline agonist | |||
| 0.066 | 0.034 | 0.066 | Carbonic anhydrase stimulant | |||
| 0.039 | 0.007 | 0.039 | Purinergic P2Y15 antagonist | |||
| 0.069 | 0.037 | 0.069 | NMDA receptor agonist | |||
| 0.115 | 0.084 | 0.115 | DNA repair enzyme inhibitor | |||
| 0.046 | 0.015 | 0.046 | Opioid delta receptor agonist | |||
| 0.088 | 0.057 | 0.088 | Acetylcholine agonist | |||
| 0.068 | 0.038 | 0.068 | Adenosine A2a receptor antagonist | |||
| 0.098 | 0.068 | 0.098 | Nav1.1 sodium channel blocker | |||
| 0.112 | 0.082 | 0.112 | MAP kinase kinase inhibitor | |||
| 0.045 | 0.015 | 0.045 | Glucose-6-phosphate dehydrogenase inhibitor | |||
| 0.07 | 0.04 | 0.07 | Adenosine A2 receptor antagonist | |||
| 0.119 | 0.089 | 0.119 | Calcium channel blocker | |||
| 0.097 | 0.068 | 0.097 | Check point kinase 2 inhibitor | |||
| 0.122 | 0.094 | 0.122 | Activin receptor-like kinase 2 inhibitor | |||
| 0.046 | 0.018 | 0.046 | Factor XIIIa inhibitor | |||
| 0.067 | 0.039 | 0.067 | Beta 3 adrenoreceptor antagonist | |||
| 0.092 | 0.065 | 0.092 | Prolactin inhibitor | |||
| 0.142 | 0.116 | 0.142 | ATPase inhibitor | |||
| 0.122 | 0.096 | 0.122 | Protein kinase (CK1) gamma 1 inhibitor | |||
| 0.155 | 0.13 | 0.155 | Neurotrophic factor enhancer | |||
| 0.061 | 0.036 | 0.061 | 5 Hydroxytryptamine 5 antagonist | |||
| 0.107 | 0.082 | 0.107 | Calcium channel N-type blocker | |||
| 0.045 | 0.021 | 0.045 | Membrane dipeptidase inhibitor | |||
| 0.113 | 0.09 | 0.113 | Cyclin-dependent kinase 7 inhibitor | |||
| 0.074 | 0.052 | 0.074 | Rho-associated kinase I inhibitor | |||
| 0.037 | 0.015 | 0.037 | GHS receptor antagonist | |||
| 0.041 | 0.019 | 0.041 | Integrin alpha2 antagonist | |||
| 0.046 | 0.025 | 0.046 | Histamine H1 receptor agonist | |||
| 0.046 | 0.026 | 0.046 | Histamine H2 receptor agonist | |||
| 0.057 | 0.037 | 0.057 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | |||
| 0.023 | 0.004 | 0.023 | CDK2/cyclin A3 inhibitor | |||
| 0.062 | 0.042 | 0.062 | Corticotropin releasing factor 2 receptor antagonist | |||
| 0.158 | 0.139 | 0.158 | Cyclic AMP phosphodiesterase inhibitor | |||
| 0.032 | 0.013 | 0.032 | Estrogen-related receptor gamma antagonist | 0.032 0.012 DBMET00322 | ||
| 0.149 | 0.13 | 0.149 | Anticonvulsant | |||
| 0.047 | 0.029 | 0.047 | Mannosidase inhibitor | |||
| 0.044 | 0.026 | 0.044 | Glutamate (mGluR1a) antagonist | |||
| 0.114 | 0.096 | 0.114 | Cytokine production inhibitor | |||
| 0.045 | 0.028 | 0.045 | Dihydrofolate reductase inhibitor | |||
| 0.061 | 0.044 | 0.061 | Acetylcholine M2 receptor antagonist | |||
| 0.112 | 0.095 | 0.112 | Antibacterial (Helicobacter pylori) | |||
| 0.13 | 0.113 | 0.13 | Protein kinase (CK1) gamma 3 inhibitor | |||
| 0.032 | 0.016 | 0.032 | CDK4/cyclin D3 inhibitor | |||
| 0.143 | 0.127 | 0.143 | Succinate dehydrogenase inhibitor | |||
| 0.027 | 0.011 | 0.027 | 5 Hydroxytryptamine 4 agonist | |||
| 0.03 | 0.015 | 0.03 | Histone deacetylase 1 inhibitor | |||
| 0.077 | 0.062 | 0.077 | Carbonic anhydrase VI inhibitor | |||
| 0.039 | 0.024 | 0.039 | Diamine oxidase inhibitor | |||
| 0.071 | 0.056 | 0.071 | Adenosine A3 receptor antagonist | |||
| 0.087 | 0.073 | 0.087 | Platelet activating factor beta antagonist | |||
| 0.041 | 0.028 | 0.041 | Thymidine kinase inhibitor | |||
| 0.065 | 0.051 | 0.065 | Potassium channel large-conductance Ca-activated activator | |||
| 0.021 | 0.008 | 0.021 | Adenosine A2a receptor agonist | |||
| 0.057 | 0.044 | 0.057 | Biliverdin reductase inhibitor | |||
| 0.038 | 0.025 | 0.038 | Histone deacetylase 7 inhibitor | |||
| 0.032 | 0.019 | 0.032 | AMPA 3 receptor antagonist | |||
| 0.099 | 0.086 | 0.099 | Calcium channel (voltage-sensitive) blocker | |||
| 0.035 | 0.023 | 0.035 | Adenosine uptake inhibitor | |||
| 0.127 | 0.114 | 0.127 | Polo-like kinase-3 inhibitor | |||
| 0.059 | 0.047 | 0.059 | NMDA 2C receptor antagonist | |||
| 0.088 | 0.076 | 0.088 | Interleukin 1 beta converting enzyme inhibitor | |||
| 0.024 | 0.013 | 0.024 | ICAM 1 antagonist | |||
| 0.1 | 0.089 | 0.1 | CDK3/cyclin E inhibitor | |||
| 0.049 | 0.039 | 0.049 | NMDA 2A receptor antagonist | |||
| 0.019 | 0.009 | 0.019 | Adenosine A2 receptor agonist | |||
| 0.082 | 0.072 | 0.082 | Fibroblast growth factor 1 antagonist | |||
| 0.055 | 0.046 | 0.055 | Botulinum neurotoxin type A inhibitor | |||
| 0.028 | 0.019 | 0.028 | Hypoxanthine phosphoribosyltransferase inhibitor | |||
| 0.2 | 0.192 | 0.2 | Ca(v)3.3 blocker | |||
| 0.057 | 0.049 | 0.057 | NMDA receptor glycine site agonist | |||
| 0.021 | 0.013 | 0.021 | Factor XIII inhibitor | |||
| 0.138 | 0.13 | 0.138 | Cyclin-dependent kinase 3 inhibitor | |||
| 0.105 | 0.098 | 0.105 | Lck kinase inhibitor | |||
| 0.045 | 0.039 | 0.045 | Benzodiazepine antagonist | |||
| 0.044 | 0.038 | 0.044 | Beta adrenoreceptor agonist | |||
| 0.075 | 0.07 | 0.075 | Glutathione S-transferase inhibitor | |||
| 0.053 | 0.047 | 0.053 | Immunoglobulin Fc receptor antagonist | |||
| 0.092 | 0.086 | 0.092 | Platelet activating factor antagonist | |||
| 0.055 | 0.051 | 0.055 | Purinergic P2X1 antagonist | |||
| 0.02 | 0.016 | 0.02 | Neuraminidase (Influenza B) inhibitor | |||
| 0.006 | 0.002 | 0.006 | Reverse transcriptase (HBV) inhibitor | |||
| 0.08 | 0.076 | 0.08 | Potassium channel activator | |||
| 0.044 | 0.041 | 0.044 | Transforming growth factor beta 1 antagonist | |||
| 0.142 | 0.139 | 0.142 | Platelet aggregation inhibitor | |||
| 0.071 | 0.067 | 0.071 | Acetylcholine nicotinic antagonist | |||
| 0.078 | 0.075 | 0.078 | Proto-oncogene tyrosine-protein kinase Kit inhibitor | |||
| 0.036 | 0.034 | 0.036 | AMPA 4 receptor antagonist | |||
| 0.037 | 0.036 | 0.037 | Acetylcholine M1 receptor agonist | |||
| 0.096 | 0.095 | 0.096 | MAO inhibitor | |||
| 0.047 | 0.046 | 0.047 | Toll-Like receptor 8 antagonist | |||
| 0.034 | 0.033 | 0.034 | ATM kinase inhibitor | |||
| 0.096 | 0.095 | 0.096 | TRKA antagonist | |||
| 0.18 | 0.255 | 0.269 | Antibacterial | 0.269 0.16 DBMET00322 | DBMET00322 | |
| 0.034 | 0.2 | 0.076 | Epidermal growth factor antagonist | 0.076 0.071 DBMET00322 | DBMET00322 | |
| 0.067 | 0.268 | 0.127 | Dual specificity phosphatase inhibitor | 0.127 0.125 DBMET00322 | DBMET00322 | |
| 0.07 | 0.306 | 0.163 | Free radical scavenger | 0.163 0.131 DBMET00322 | DBMET00322 | |
| 0.074 | 0.325 | 0.184 | Antioxidant | 0.184 0.128 DBMET00322 | DBMET00322 | |
| 0.023 | 0.3 | 0.146 | M18 aspartyl aminopeptidase inhibitor | 0.146 0.054 DBMET00322 | DBMET00322 | |
| 0.015 | 0.514 | 0.11 | Cyclooxygenase 1 inhibitor | 0.11 0.09 DBMET00322 | DBMET00322 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |